Download PDF
Nervenheilkunde 2016; 35(11): 748-751
DOI: 10.1055/s-0037-1616446
Sucht
Schattauer GmbH

Stellenwert der Disulfiramtherapie heute?

Status of disulfiram today?
J. Mutschler
1   Privatklinik Meiringen, Schweiz
2   Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Zentrum für Abhängigkeitserkrankungen, Psychiatrische Universitätsklinik Zürich, Schweiz
,
M. Grosshans
3   Klinik für Abhängiges Verhalten und Suchtmedizin, Zentralinstitut für Seelische Gesundheit, Medizinische Fakultät Mannheim/ Universität Heidelberg, Mannheim
› Author Affiliations
Further Information

Publication History

eingegangen am: 13 June 2016

angenommen am: 10 August 2016

Publication Date:
10 January 2018 (online)

    Permissions and Reprints

Zusammenfassung

Disulfiram nimmt in der Suchtmedizin eine besondere, oftmals kontroverse, Rolle ein. Das Medikament ist inzwischen über 60 Jahre für die Behandlung der Alkoholabhängigkeit in vielen Ländern zugelassen. Seit 2011 ist Disulfiram in Deutschland formal allerdings nicht mehr zugelassen, kann aber weiterhin als „Off-lable“-Medikament eingesetzt und über Auslandsapotheken bezogen werden. Dieser Umstand und eine mögliche Ausweitung der Einsatzgebiete machen neben dem Wissen um die therapeutischen Effekte auch fundierte Kenntnisse um Wirkung, Wechselwirkungen, Kontraindikationen und Nebenwirkungen von Disulfiram erforderlich. In der folgenden Übersicht soll eine aktuelle Überblick gegeben werden.

Summary

Disulfiram has in addiction medicine a special, often controversial, role. The drug is approved for more than 60 years for the treatment of alcohol dependence in many countries. Since 2011 disulfiram is in Germany formal, but no longer permitted, but may continue to be used as off-lable drug and based on foreign pharmacies. This circumstance, and the possible extension of application in other diseases, make, in addition to the knowledge of the therapeutic effects, also sound knowledge to action, interactions, contraindications and side effects of disulfiram required. The following paper should give a current overview.

Schlüsselwörter

Disulfiram - Alkoholabhängigkeit - Alkoholrückfallprophylaxe

Keywords

Disulfiram - alcohol addiction - alcohol relapse prevention
 

  • Literatur

  • 1 Goldman D, Oroszi G, Ducci F. The genetics of addictions: uncovering the genes. Nat Rev Genet 2005; 6 (07) 521-32.
    CrossrefPubMedGoogle Scholar
  • 2 Mann K, Laucht M, Weyerer S. [Addiction across the lifespan]. Nervenarzt 2009; 80 (11) 1293-301.
    CrossrefPubMedGoogle Scholar
  • 3 Rehm J. et al. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 2009; 373 (9682): 2223-33.
    CrossrefPubMedGoogle Scholar
  • 4 Spanagel R. Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiol Rev 2009; 89 (02) 649-705.
    CrossrefPubMedGoogle Scholar
  • 5 Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology 2010; 35 (01) 217-38.
    CrossrefPubMedGoogle Scholar
  • 6 Hermann D. et al. Translational magnetic resonance spectroscopy reveals excessive central glutamate levels during alcohol withdrawal in humans and rats. Biol Psychiatry 2012; 71 (11) 1015-21.
    CrossrefPubMedGoogle Scholar
  • 7 Spanagel R. et al. The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption. Nat Med 2005; 11 (01) 35-42.
    CrossrefPubMedGoogle Scholar
  • 8 Heilig M, Egli M. Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther 2006; 111 (03) 855-76.
    CrossrefPubMedGoogle Scholar
  • 9 Spanagel R, Kiefer F. Drugs for relapse prevention of alcoholism: ten years of progress. Trends Pharmacol Sci 2008; 29 (03) 109-15.
    CrossrefPubMedGoogle Scholar
  • 10 Mann K, Kiefer F, Spanagel R, Littleton J. Acamprosate: recent findings and future research directions. Alcohol Clin Exp Res 2008; 32 (07) 1105-10.
    CrossrefPubMedGoogle Scholar
  • 11 Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 2004; 28 (01) 51-63.
    CrossrefPubMedGoogle Scholar
  • 12 Srisurapanont M, Jarusuraisin N. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2005; 8 (02) 267-80.
    CrossrefPubMedGoogle Scholar
  • 13 Suh JJ, Pettinati HM, Kampman KM, O‘Brien CP. The status of disulfiram: a half of a century later. J Clin Psychopharmacol 2006; 26 (03) 290-302.
    CrossrefPubMedGoogle Scholar
  • 14 Banys P. The clinical use of disulfiram (Antabuse): a review. J Psychoactive Drugs 1988; 20 (03) 243-61.
    CrossrefPubMedGoogle Scholar
  • 15 Hald J, Jacobsen E. A drug sensitizing the organism to ethyl alcohol. Lancet 1948; 2 (6539): 1001-4.
    PubMedGoogle Scholar
  • 16 Diehl A. et al. Why is disulfiram superior to acamprosate in the routine clinical setting? A retrospective long-term study in 353 alcohol-dependent patients. Alcohol Alcohol 2010; 45 (03) 271-7.
    CrossrefPubMedGoogle Scholar
  • 17 Krampe H, Ehrenreich H. Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment. Curr Pharm Des 2010; 16 (19) 2076-90.
    CrossrefPubMedGoogle Scholar
  • 18 Krampe H. et al. Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome. Alcohol Clin Exp Res 2006; 30 (01) 86-95.
    CrossrefPubMedGoogle Scholar
  • 19 Mutschler et al. [Recent results in relaps prevention of alcoholism with Disulfiram]. Neuropsychiatr 2008; 22 (04) 243-51.
    PubMedGoogle Scholar
  • 20 Mutschler J, Diehl A, Kiefer F. [Pharmacology of disulfiram – an update]. Fortschr Neurol Psychiatr 2008; 76 (04) 225-31.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Madan A, Parkinson A, Faiman MD. Identification of the human P-450 enzymes responsible for the sulfoxidation and thiono-oxidation of diethyldithiocarbamate methyl ester: role of P-450 enzymes in disulfiram bioactivation. Alcohol Clin Exp Res 1998; 22 (06) 1212-9.
    PubMedGoogle Scholar
  • 22 Johansson B. A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr Scand Suppl 1992; 369: 15-26.
    Google Scholar
  • 23 Elenbaas RM. Drug therapy reviews: management of the disulfiram-alcohol reaction. Am J Hosp Pharm 1977; 34 (08) 827-31.
    PubMedGoogle Scholar
  • 24 Amadoe Gazdar A. Sudden death durin disulfiram – alcohol reaction. Q J Stud Alcohol 1967; 28 (04) 649-54.
    PubMedGoogle Scholar
  • 25 Guild J, Epstein NB. Psychosis during the treatment of alcoholism with tetraethylthiuram disulfide. Q J Stud Alcohol 1951; 12 (03) 360-6.
    PubMedGoogle Scholar
  • 26 Jacobsen E. Deaths of alcoholic patients treated with disulfiram (tetraethylthiuram disulfide) in Denmark. Q J Stud Alcohol 1952; 13 (01) 16-26.
    PubMedGoogle Scholar
  • 27 Fuller RK. et al. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA 1986; 256 (11) 1449-55.
    CrossrefPubMedGoogle Scholar
  • 28 Fuller RK, Gordis E. Does disulfiram have a role in alcoholism treatment today?. Addiction 2004; 99 (01) 21-4.
    CrossrefPubMedGoogle Scholar
  • 29 Mutschler J. et al. Functional social support within a medical supervised outpatient treatment program. Am J Drug Alcohol Abuse 2013; 39 (01) 44-9.
    CrossrefPubMedGoogle Scholar
  • 30 Ehrenreich H, Krampe H. Does disulfiram have a role in alcoholism treatment today? Not to forget about disulfiram‘s psychological effects. Addiction 2004; 99 (01) 26-7.
    CrossrefPubMedGoogle Scholar
  • 31 Mutschler J, Dirican G, Funke S, Obermann C, Grosshans M, Mann K. et al. Experienced acetaldehyde reaction does not improve treatment response in outpatients treated with supervised disulfiram. Clin Neuropharmacol 2011; 34 (04) 161-5.
    CrossrefPubMedGoogle Scholar
  • 32 Mays DC, Ortiz-Bermudez P, Lam JP, Tong IH, Fauq AH, Lipsky JJ. Inhibition of recombinant human mitochondrial aldehyde dehydrogenase by two intermediate metabolites of disulfiram. Biochem Pharmacol 1998; 55 (07) 1099-103.
    CrossrefPubMedGoogle Scholar
  • 33 Karamanakos PN, Pappas P, Stephanou P, Marselos M. Differentiation of disulfiram effects on central catecholamines and hepatic ethanol metabolism. Pharmacol Toxicol 2001; 88 (02) 106-10.
    CrossrefPubMedGoogle Scholar
  • 34 Musacchio JM, Goldstein M, Anagnoste B, Poch G, Kopin IJ. Inhibition of dopamine-beta-hydroxylase by disulfiram in vivo. J Pharmacol Exp Ther 1966; 152 (01) 56-61.
    PubMedGoogle Scholar
  • 35 Amit Z, Levitan DE, Lindros KO. Suppression of ethanol intake following administration of dopamine-beta-hydroxylase inhibitors in rats. Arch Int Pharmacodyn Ther 1976; 223 (01) 114-9.
    PubMedGoogle Scholar
  • 36 Kohnke MD. et al. A genotype-controlled analysis of plasma dopamine beta-hydroxylase in healthy and alcoholic subjects: evidence for alcohol-related differences in noradrenergic function. Biol Psychiatry 2002; 52 (12) 1151-8.
    CrossrefPubMedGoogle Scholar
  • 37 Kohnke MD. et al. DBH*444G/A polymorphism of the dopamine-beta-hydroxylase gene is associated with alcoholism but not with severe alcohol withdrawal symptoms. J Neural Transm 2006; 113 (07) 869-76.
    CrossrefPubMedGoogle Scholar
  • 38 Mutschler J. et al. Functional Polymorphism of the Dopamine beta-Hydroxylase Gene Is Associated With Increased Risk of Disulfiram-Induced Adverse Effects in Alcohol-Dependent Patients. J Clin Psychopharmacol 2011; 32 (04) 578-80.
    Google Scholar
  • 39 Muller CA, Banas R. Disulfiram: an anticraving substance?. Am J Psychiatry 2011; 168 (01) 98.
    PubMedGoogle Scholar
  • 40 Krampe H. et al. Personality disorder and chronicity of addiction as independent outcome predictors in alcoholism treatment. Psychiatr Serv 2006; 57 (05) 708-12.
    CrossrefPubMedGoogle Scholar
  • 41 Mutschler J. et al. Supervised disulfiram in relapse prevention in alcohol-dependent patients suffering from comorbid borderline personality disorder – a case series. Alcohol Alcohol 2010; 45 (02) 146-50.
    CrossrefPubMedGoogle Scholar
  • 42 Hughes JC, Cook CC. The efficacy of disulfiram: a review of outcome studies. Addiction 1997; 92 (04) 381-95.
    CrossrefPubMedGoogle Scholar
  • 43 Petrakis I. et al. Naltrexone and disulfiram in patients with alcohol dependence and current depression. J Clin Psychopharmacol 2007; 27 (02) 160-5.
    CrossrefPubMedGoogle Scholar
  • 44 Petrakis IL. et al. Naltrexone and disulfiram in patients with alcohol dependence and comorbid post-traumatic stress disorder. Biol Psychiatry 2006; 60 (07) 777-83.
    CrossrefPubMedGoogle Scholar
  • 45 Petrakis IL, Poling J, Levinson C, Nich C, Carroll K, Rounsaville B. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol Psychiatry 2005; 57 (10) 1128-37.
    CrossrefPubMedGoogle Scholar
  • 46 Christensen JK, Ronsted P, Vaag UH. Side effects after disulfiram. Comparison of disulfiram and placebo in a double-blind multicentre study. Acta Psychiatr Scand 1984; 69 (04) 265-73.
    CrossrefPubMedGoogle Scholar
  • 47 Chick J. Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Saf 1999; 20 (05) 427-35.
    CrossrefPubMedGoogle Scholar
  • 48 Mutschler J, Dirican G, Gutzeit A, Grosshans M. Safety and efficacy of long-term disulfiram aftercare. Clin Neuropharmacol 2011; 34 (05) 195-8.
    CrossrefPubMedGoogle Scholar
  • 49 Mutschler J, Diehl A, Kiefer F. Pronounced paranoia as a result of cocaine-disulfiram interaction: case report and mode of action. J Clin Psychopharmacol 2009; 29 (01) 99-101.
    CrossrefPubMedGoogle Scholar
  • 50 Major LF, Lerner P, Ballenger JC, Brown GL, Goodwin FK, Lovenberg W. Dopamine-beta-hydroxylase in the cerebrospinal fluid: relationship to disulfiram-induced psychosis. Biol Psychiatry 1979; 14 (02) 337-44.
    PubMedGoogle Scholar
  • 51 Branchey L, Davis W, Lee KK, Fuller RK. Psychiatric complications of disulfiram treatment. Am J Psychiatry 1987; 144 (10) 1310-2.
    CrossrefPubMedGoogle Scholar
  • 52 Bjornsson E, Nordlinder H, Olsson R. Clinical characteristics and prognostic markers in disulfiram-induced liver injury. J Hepatol 2006; 44 (04) 791-7.
    CrossrefPubMedGoogle Scholar
  • 53 Frisoni GB, Di Monda V. Disulfiram neuropathy: a review (1971–1988) and report of a case. Alcohol Alcohol 1989; 24 (05) 429-37.
    PubMedGoogle Scholar
  • 54 Anton RF. et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 2008; 65 (02) 135-44.
    CrossrefPubMedGoogle Scholar
  • 55 Oslin DW. et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003; 28 (08) 1546-52.
    CrossrefPubMedGoogle Scholar
  • 56 Kiefer F. et al. Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate. Pharmacogenomics J 2011; 11 (05) 368-74.
    CrossrefPubMedGoogle Scholar
  • 57 Heilig M, Goldman D, Berrettini W, O‘Brien CP. Pharmacogenetic approaches to the treatment of alcohol addiction. Nat Rev Neurosci 2011; 12 (11) 670-84.
    CrossrefPubMedGoogle Scholar
  • 58 Finney JW, Monahan SC. The cost-effectiveness of treatment for alcoholism: a second approximation. J Stud Alcohol 1996; 57 (03) 229-43.
    CrossrefPubMedGoogle Scholar
  • 59 Miller WR, Wilbourne PL. Mesa Grande: a methodological analysis of clinical trials of treatments for alcohol use disorders. Addiction 2002; 97 (03) 265-77.
    CrossrefPubMedGoogle Scholar
  • 60 Wilson A. et al. Disulfiram implantation. A placebo-controlled trial with two-year follow-up. J Stud Alcohol 1978; 39 (05) 809-19.
    CrossrefPubMedGoogle Scholar
  • 61 Kellam AM, Wesolkowski JM. Disulfiram implantation for alcoholism. Lancet 1968; 1 (7548): 925-6.
    PubMedGoogle Scholar
  • 62 Mutschler J. et al. Urinary ethylglucuronide assessment in patients treated with disulfiram: a tool to improve verification of abstention and safety. Clin Neuropharmacol 2010; 33 (06) 285-7.
    CrossrefPubMedGoogle Scholar
  • 63 Carroll KM. et al. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry 2004; 61 (03) 264-72.
    CrossrefPubMedGoogle Scholar
  • 64 Muller CA. et al. Treatment of pathological gambling with disulfiram: a report of 2 cases. Pharmacopsychiatry 2011; 44 (02) 81-3.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 65 Mutschler J. et al. Disulfiram, an old drug with new potential in the treatment of pathological gambling?. Med Hypotheses 2010; 74 (01) 209-10.
    CrossrefPubMedGoogle Scholar
  • 66 Mutschler J. et al. Disulfiram, an option for the treatment of pathological gambling?. Alcohol Alcohol 2010; 45 (02) 214-6.
    CrossrefPubMedGoogle Scholar